Author:
Penel Nicolas,Adenis Antoine,Bonneterre Jacques
Reference11 articles.
1. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes;Gabizon;Cancer Res,1994
2. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer;O'Brien;Ann Oncol,2004
3. Moore MR, Srinivasiah J, Feinberg BA, et al. Phase II randomized trial of doxorubicin plus paclitaxel (AT) versus doxorubicin HCl liposome injection (Doxil) plus paclitaxel (DT) in metastatic breast cancer. 34th Annual Meeting of the American Society of Clinical Oncology; Los Angeles, CA; May 16–19, 1998. Abstr 614.
4. Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study;Mamot;Lancet Oncol,2012
5. Phase I and phamacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer;Matsumara;Ann Oncol,2004